专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008126039A3 CELL LINES, COMPOSITIONS COMPRISING THEM FOR THE TREATMENT OF MELANOMAS, PROCEDURES TO PREPARE THE COMPOSITIONS, AND TREATMENT METHODS 审中-公开
标题翻译：细胞系，包含它们的组合物，用于治疗MELANOMAS，制备组合物的程序和治疗方法
公开(公告)号：WO2008126039A3
公开(公告)日：2008-12-11
申请号：PCT/IB2008051385
申请日：2008-04-11
申请人： CONSEJO NAC INVEST CIENT TEC , FUNDACION SALES , INIS BIOTECH LLC , MORDOH JOSE , BARRIO MARIA MARCELA , VON EUW ERIKA MARIA
发明人： MORDOH JOSE , BARRIO MARIA MARCELA , VON EUW ERIKA MARIA
IPC分类号： A61K39/00 , C12N5/06
CPC分类号： A61K39/0011 , A61K2039/5152 , A61K2039/5154
摘要： CeIl lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods. More particularly, the invention relates to diverse human melanoma cell lines for the treatment of malignant diseases, wherein the cell lines are: (a) MeI-XYl (deposited at German Collection of Microorganisms and Cell Cultures DSMZ under access number DSM ACC2830), (b) Mel-XY2 (deposited at Germán Collection of Microorganisms and Cell Cultures DSMZ under access number DSM ACC2831), (c) Mel-XY3 (deposited at Germán Collection of Microorganisms and Cell Cultures DSMZ under access number DSM ACC2832), (d) Mel-XX4 (deposited at Germán Collection of Microorganisms and Cell Cultures DSMZ under access number DSM ACC2829), or (e) sub-populations thereof. The cell lines may be irradiated, thus obtaining populations with apoptotic phenotype, and populations with necrotic phenotype of such lines. The compositions may comprise adjuvants and/or immuno-modif iers, and/or autologous dendritic cells.
摘要翻译： CeIl系列，包含它们用于治疗黑素瘤的组合物，制备组合物的程序和治疗方法。更具体地，本发明涉及用于治疗恶性疾病的多种人黑素瘤细胞系，其中细胞系是：（a）MeI-XY1（保藏于德国收藏的微生物和细胞培养物DSMZ，存取号DSM ACC2830），（ b）Mel-XY2（保藏于Germán收集的微生物和细胞培养物DSMZ，存取号码为DSM ACC2831），（c）Mel-XY3（保藏于GermánCollection of Microorganisms and Cell Cultures DSMZ，access number DSM ACC2832），（d） Mel-XX4（保藏于GermánCollection of Microorganisms and Cell Cultures DSMZ in access number DSM ACC2829），或（e）其亚群。可以照射细胞系，从而获得具有凋亡表型的群体以及具有坏死表型的群体。组合物可以包含佐剂和/或免疫修饰剂和/或自体树突状细胞。

2. 发明申请

WO2008126039A2 CELL LINES, COMPOSITIONS COMPRISING THEM FOR THE TREATMENT OF MELANOMAS, PROCEDURES TO PREPARE THE COMPOSITIONS, AND TREATMENT METHODS 审中-公开
标题翻译：细胞系，包含它们的组合物用于治疗梅拉诺马斯，制备组合物的程序和治疗方法
公开(公告)号：WO2008126039A2
公开(公告)日：2008-10-23
申请号：PCT/IB2008/051385
申请日：2008-04-11
申请人： CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TÉCNICAS (CONICET) , FUNDACION SALES , INIS BIOTECH LLC , MORDOH, José , BARRIO, María Marcela , VON EUW, Erika María
发明人： MORDOH, José , BARRIO, María Marcela , VON EUW, Erika María
IPC分类号： C12N15/11
CPC分类号： A61K39/0011 , A61K2039/5152 , A61K2039/5154
摘要： CeIl lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods. More particularly, the invention relates to diverse human melanoma cell lines for the treatment of malignant diseases, wherein the cell lines are: (a) MeI-XYl (deposited at German Collection of Microorganisms and Cell Cultures DSMZ under access number DSM ACC2830), (b) Mel-XY2 (deposited at Germán Collection of Microorganisms and Cell Cultures DSMZ under access number DSM ACC2831), (c) Mel-XY3 (deposited at Germán Collection of Microorganisms and Cell Cultures DSMZ under access number DSM ACC2832), (d) Mel-XX4 (deposited at Germán Collection of Microorganisms and Cell Cultures DSMZ under access number DSM ACC2829), or (e) sub-populations thereof. The cell lines may be irradiated, thus obtaining populations with apoptotic phenotype, and populations with necrotic phenotype of such lines. The compositions may comprise adjuvants and/or immuno-modif iers, and/or autologous dendritic cells.
摘要翻译：细胞系，包含它们的组合物用于治疗黑素瘤，制备组合物的方法和治疗方法。更具体地说，本发明涉及用于治疗恶性疾病的多种人黑素瘤细胞系，其中细胞系是：（a）MeI-XY1（以保藏号DSM ACC2830保藏在德国微生物和细胞培养物保藏中心DSMZ），（ b）Mel-XY2（保藏在Germ＆amp; aacute微生物和细胞培养物保藏中心DSMZ，保藏号DSM ACC2831），（c）Mel-XY3（保藏在Germ＆amp; aacute微生物和细胞培养物保藏中心DSMZ，保藏号DSM ACC2832），（d）Mel-XX4（以微生物和细胞培养物DSMZ保藏在获取号DSM ACC2829下），或（e）其亚群。可以照射细胞系，从而获得具有凋亡表型的群体，以及具有这些系的坏死表型的群体。组合物可以包含佐剂和/或免疫修饰剂，和/或自体树突细胞。

3. 发明申请

WO2011060272A3 COMPOSITIONS, KITS, AND METHODS FOR THE DIAGNOSIS, PROGNOSIS, MONITORING, TREATMENT AND MODULATION OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AND HYPOXIA ASSOCIATED ANGIOGENESIS DISORDERS USING GALECTIN-1 审中-公开
标题翻译：使用GALECTIN-1诊断，预后，监测，治疗和调节移植后淋巴增殖性病症和与缺氧相关的血管发生性疾病的组合物，试剂盒和方法
公开(公告)号：WO2011060272A3
公开(公告)日：2011-05-19
申请号：PCT/US2010/056547
申请日：2010-11-12
申请人： DANA-FARBER CANCER INSTITUTE, INC. , THE BRIGHAM AND WOMEN' S HOSPITAL, INC. , CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICET) , FUNDACION SALES , SHIPP, Margaret, A. , OUYANG, Jing , TAKEYAMA, Kunihiko , KUTOK, Jeffery L. , RODIG, Scott J. , RABINOVICH, Gabriel , RUSSO, Diego, Omar, Croci , SALATINO, Mariana
发明人： SHIPP, Margaret, A. , OUYANG, Jing , TAKEYAMA, Kunihiko , KUTOK, Jeffery L. , RODIG, Scott J. , RABINOVICH, Gabriel , RUSSO, Diego, Omar, Croci , SALATINO, Mariana
IPC分类号： C07K16/18 , C07K16/46 , C12N15/13 , G01N33/577 , A61K39/395
摘要： The present invention is based, in part, on the discovery that galectin-1 (Gall) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.
摘要翻译：本发明部分基于半乳糖凝集素-1（Gall）在病毒相关PTLD中发挥作用的发现，例如与EBV相关的PTLD和缺氧相关的血管发生病症。因此，本发明涉及用于诊断，预测，监测，治疗和调节病毒相关PTLD（例如EBV相关PTLD和缺氧相关血管生成病症）的组合物，试剂盒和方法。

4. 发明申请

US20170037120A1 Methods for Modulating Angiogenesis of Cancers Refractory to Anti-VEGF Treatment 审中-公开
$Methods for Modulating Angiogenesis of Cancers Refractory to Anti-VEGF Treatment$
标题翻译：调节抗VEGF治疗难治性癌症血管生成的方法
公开(公告)号：US20170037120A1
公开(公告)日：2017-02-09
申请号：US15100164
申请日：2014-11-26
申请人： INIS BIOTECH LLC , CONSEJO NACIONAL DE INVESTIGACIONES CIENTÍFICAS Y TÉCNICAS (CONICET) , FUNDACION SALES
发明人： Gabriel Adrian Rabinovich , Diego Omar Croci Russo , Juan Pablo Cerliani , Mariana Salatino
IPC分类号： C07K16/22 , C07K16/26
CPC分类号： C07K16/22 , A61K2039/505 , A61K2039/507 , C07K16/18 , C07K16/26 , C07K16/30 , C07K2317/76
摘要： A method for modulating angiogenesis in a cancer or tumor refractory to anti-VEGF, including identifying a cancer cell as being referactory to anti-VEGF, and then contacting the cancer cell refractory to anti-VEGF with an effective amount of an agent that modulates interaction between Gal1 or a Gal1 fragment and the natural binding partner of Gal1 or the Gal1 fragment to thereby modulate angiogenesis.
摘要翻译：一种用于调节抗VEGF不良反应的癌症或肿瘤的血管发生的方法，包括将癌细胞识别为参与抗VEGF，然后使难治性的抗VEGF与有效量的调节相互作用的试剂接触 Gal1或Gal1片段与Gal1或Gal1片段的天然结合配偶体之间，从而调节血管发生。

5. 发明申请

WO2013086379A3 METHODS AND COMPOSITIONS FOR TREATING ANTIPROGESTIN-RESISTANT CANCERS 审中-公开
标题翻译：用于治疗抗耐药性癌症的方法和组合物
公开(公告)号：WO2013086379A3
公开(公告)日：2013-08-22
申请号：PCT/US2012068525
申请日：2012-12-07
申请人： FUNDACION SALES , CONSEJO NAC INVEST CIENT TEC , LANARI CLAUDIA LEE
发明人： LANARI CLAUDIA LEE , WARGON VICTORIA , ROJAS PAOLA , MAY MARIA , SEQUEIRA GONZALO
IPC分类号： A61K31/70 , A61K31/16 , A61K31/165 , A61K31/167 , A61P35/00
CPC分类号： A61K38/1783 , A61K31/165 , A61K31/567 , A61K31/575 , A61K31/706 , A61K31/7068 , A61K45/06 , A61K48/005 , A61K2300/00
摘要： The invention provides methods, pharmaceutical compositions and kits for treating a subject having a carcinoma that is resistant to an antiprogestin. In particular, the methods comprise increasing the molar amount of progesterone receptor isoform A (PR-A) so that it is greater than that of isoform B (PR-B) and administering a therapeutically effective amount of an antiprogestin to the subject, thereby treating the carcinoma.
摘要翻译：本发明提供了用于治疗患有对抗孕激素有抗性的癌症的受试者的方法，药物组合物和试剂盒。特别地，所述方法包括增加孕酮受体同种型A（PR-A）的摩尔量，使其大于同种型B（PR-B）的摩尔量，并向受试者施用治疗有效量的抗孕激素，从而治疗癌。

6. 发明申请

WO2013086379A2 METHODS AND COMPOSITIONS FOR TREATING ANTIPROGESTIN-RESISTANT CANCERS 审中-公开
标题翻译：治疗抗原癌症的方法和组合物
公开(公告)号：WO2013086379A2
公开(公告)日：2013-06-13
申请号：PCT/US2012/068525
申请日：2012-12-07
申请人： FUNDACION SALES , CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS , LANARI, Claudia, Lee
发明人： LANARI, Claudia, Lee , WARGON, Victoria , ROJAS, Paola , MAY, Maria , SEQUEIRA, Gonzalo
IPC分类号： A61K31/70 , A61K31/165 , A61K31/16 , A61K31/167 , A61P35/00
CPC分类号： A61K38/1783 , A61K31/165 , A61K31/567 , A61K31/575 , A61K31/706 , A61K31/7068 , A61K45/06 , A61K48/005 , A61K2300/00
摘要： The invention provides methods, pharmaceutical compositions and kits for treating a subject having a carcinoma that is resistant to an antiprogestin. In particular, the methods comprise increasing the molar amount of progesterone receptor isoform A (PR-A) so that it is greater than that of isoform B (PR-B) and administering a therapeutically effective amount of an antiprogestin to the subject, thereby treating the carcinoma.
摘要翻译：本发明提供了用于治疗患有对抗孕酮具有抗性的癌症的受试者的方法，药物组合物和试剂盒。具体而言，所述方法包括增加孕酮受体同种型A（PR-A）的摩尔量以使其大于同种型B（PR-B）的摩尔量并将治疗有效量的抗孕激素给予受试者，由此治疗癌。

7. 发明授权

US11723972B2 Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 有权
公开(公告)号：US11723972B2
公开(公告)日：2023-08-15
申请号：US16573374
申请日：2019-09-17
申请人： Dana-Farber Cancer Institute, Inc. , The Brigham and Women's Hospital, Inc. , Consejo Nacional de Investigaciones Cientificas y Técnicas (CONICET) , Fundacion Sales
发明人： Margaret Shipp , Jing Ouyang , Kunihiko Takeyama , Jeffery L. Kutok , Scott J. Rodig , Gabriel Rabinovich , Diego Omar Croci Russo , Mariana Salatino
IPC分类号： G01N33/574 , G01N33/563 , C07K16/30 , A61K39/395 , C07K16/18 , C07K16/22 , A61K45/06 , A61K39/00
CPC分类号： A61K39/3955 , A61K45/06 , C07K16/18 , C07K16/22 , A61K2039/505 , C07K2317/34 , C07K2317/73 , C07K2317/76
摘要： The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.

8. 发明授权

US10456465B2 Compositions, kits, and methods for the diagnosis prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 有权
公开(公告)号：US10456465B2
公开(公告)日：2019-10-29
申请号：US14598405
申请日：2015-01-16
申请人： Dana-Farber Cancer Institute, Inc. , The Brigham and Women's Hospital, Inc. , Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) , Fundacion Sales
发明人： Margaret A. Shipp , Jing Ouyang , Kunihiko Takeyama , Jeffery L. Kutok , Scott J. Rodig , Gabriel Rabinovich , Diego Omar Croci Russo , Mariana Salatino
IPC分类号： A61K39/395 , C07K16/44 , C07K16/18 , C07K16/22 , A61K45/06 , A61K39/00
摘要： The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.

9. 发明申请

US20200093920A1 COMPOSITIONS, KITS, AND METHODS FOR THE DIAGNOSIS, PROGNOSIS, MONITORING, TREATMENT AND MODULATION OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS AND HYPOXIA ASSOCIATED ANGIOGENESIS DISORDERS USING GALECTIN-1 审中-公开
公开(公告)号：US20200093920A1
公开(公告)日：2020-03-26
申请号：US16573374
申请日：2019-09-17
申请人： Dana-Farber Cancer Institute, Inc. , The Brigham and Women's Hospital, Inc. , Consejo Nactional De Investigaciones Cientificias Y Técnicas (CONICET) , Fundacion Sales
发明人： Margaret A. Shipp , Jing Ouyang , Kunihiko Takeyama , Jeffery L. Kutok , Scott J. Rodig , Gabriel Rabinovich , Diego O. Russo , Mariana Salatino
IPC分类号： A61K39/395 , C07K16/18 , C07K16/22 , A61K45/06
摘要： The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders. Accordingly, the invention relates to compositions, kits, and method for diagnosing, prognosing, monitoring, treating and modulating viral-associated PTLD, e.g., EBV-associated PTLD and hypoxia associated angiogenesis disorders.

10. 发明申请

US20160187340A1 Compositions, Kits, and Methods for the Modulation of Immune Responses Using Galectin-1 审中-公开
公开(公告)号：US20160187340A1
公开(公告)日：2016-06-30
申请号：US14927802
申请日：2015-10-30
申请人： Dana-Farber Cancer Institute, Inc. , Consejo Nactional De Investigaciones Cientificias Y Tecnicas , Fundacion Sales
发明人： Margaret A. Shipp , Przemyslaw Juszczynski , Jing Ouyang , Jeffery L. Kutok , Scott J. Rodig , Gabriel Rabinovich
IPC分类号： G01N33/574 , C07K16/30 , A61K45/06 , A61K39/395 , C07K16/28
CPC分类号： G01N33/57407 , A61K39/395 , A61K39/39533 , A61K39/3955 , A61K45/06 , A61K2039/585 , C07K16/28 , C07K16/3061 , C07K2317/76 , C12N15/1138 , C12N2310/14 , G01N33/5011 , G01N2333/47 , G01N2500/00
摘要： The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma. Accordingly, the invention relates to compositions, kits, and methods for detecting, characterizing, modulating, preventing, and treating immune disorders, e.g., Hodgkin lymphoma.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式